Clinical trial

Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance

NCT01819389

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-10-01

PhasePHASE3

Study timeline

Study start (unknown)2012-10-01Date precision: month

Registry last updated2014-01-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Leukemia, Myeloid, Chronic, BCR-ABL Positiveunresolved

Interventions

Imatinib and NilotinibDRUG

Sponsors & collaborators

Hospital Universitario Dr. Jose E. Gonzalezlead sponsor

Novartis Pharmaceuticalscollaborator

Mapped research locations

MonterreyNuevo León, Mexico1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01819389 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.